ArticleMetabolism open2025
Elevated fasting glucose is common in lung cancer patients undergoing 18F-FDG PET/CT: A brief report.
Article in Metabolism open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To characterize glycemic profiles among patients with lung cancer undergoing standardized capillary fasting blood glucose (cFBG) assessment prior to fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging. Material and methods: Consecutive lung cancer patients scheduled for FDG PET/CT were enrolled at the University Hospital Zurich. cFBG was measured before FDG PET/CT and classified according to American Diabetes Association guidelines. Additional analyses were performed in subgroups examined before 11 a.m. and in patients without known diabetes. Multivariable linear regression was used to identify independent factors associated with cFBG levels. Results: The cohort included 240 lung cancer patients (median age 67 years, IQR 60-73; 41 % female, 99/240; median BMI 24 kg/m Conclusion: More than half of lung cancer patients presenting for PET/CT had non-normal fasting glucose levels, even in the absence of traditional risk factors or known diabetes, underscoring the need for improved screening and management strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.